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Background: Systems biology experiments generate large volumes of data of
multiple modalities and this information presents a challenge for integration due to
a mix of complexity together with rich semantics. Here, we describe how graph
databases provide a powerful framework for storage, querying and envisioning of
biological data.
Results: We show how graph databases are well suited for the representation of
biological information, which is typically highly connected, semi-structured and
unpredictable. We outline an application case that uses the Neo4j graph database for
building and querying a prototype network to provide biological context to asthma
related genes.
Conclusions: Our study suggests that graph databases provide a flexible solution for
the integration of multiple types of biological data and facilitate exploratory data
mining to support hypothesis generation.
Keywords: Disease management platform, Graph database, Neo4j graph,
Protein-centric framework, Systems medicine, Computational approachIntroduction
A major effort in translational medicine is to understand the molecular basis of disease
[1, 2]. Analysis of high-throughput experimental data together with patient phenotypic
information has led to the identification of sets of candidate genes, proteins and path-
ways that may be implicated in many disease conditions.
However, in order to build a higher level picture of the underlying processes involved
in the disease pathology, it is necessary to integrate various classes of heterogeneous
information, and to explore the complex relationships between entities such as dis-
eases, candidate genes, proteins, interactions and pathways. These relationships could
have a variety of different types, like participation (protein A participates in Pathway
X), sequence similarity (protein A is sequence similar to protein B) or protein inter-
action (protein A interacts with protein B), and typically, will be associated with some
provenance information. Generally, the relationships will describe complex networks.
Some genes or proteins, for example, may be associated with multiple diseases, while
others may be implicated in only one or two conditions. Additionally, some candidate
genes may encode large families of sequence-similar proteins, and may thus be© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International
License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium,
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and
indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
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ships between entities can help in providing biological context and in hypothesis gener-
ation on disease mechanisms. Traversing paths through the generated network can
suggest hitherto unexpected relationships between entities, (e.g. relationships between
disease conditions).
Biological information is typically highly connected, semi-structured and unpredict-
able, and these features are important in deciding an appropriate way to represent and
query disease-relevant biomedical networks. Representing multiple types of relation-
ships will generally lead to highly connected networks. Additionally, the amount of in-
formation associated with a given entity will not be uniform. Some proteins have been
extensively investigated experimentally, are well annotated and associated with multiple
complementary pieces of information. For example, a gene may be involved in a
protein-protein interaction with another protein, may be a drug target for a particular
drug, may be known to be enhanced in a particular tissue type or may participate in a
particular pathway. Other proteins can have little or no information associated with
them and are annotated only as ‘hypothetical proteins’. Therefore, such datasets do not
naturally fit into a classic relational database model which would have been originally
designed to handle application cases with a large number of uniform entries associated
with a limited number of data types and representing relatively few relationships in
each data model. Although highly connected and sparse networks can be stored in a re-
lational database, generally traversal-type queries (joins), which connect data linked by
different relationships, become too computationally expensive and cumbersome to de-
sign. Traversal type queries are important for hypothesis generation, as they can reveal
paths connecting entities that might not have been expected, and might not be appar-
ent from visual inspection of the network. Another issue is that biological data are
often semi-structured, i.e. lacking a structured data model, while still possessing some
semantic annotation. As relational databases require all data to be transformed to con-
form to a pre-defined schema, developing parsers for such semi-structured data can be
particularly problematic. Biological research is also unpredictable in that new types of
information can emerge with little advance notice – for example when new analytical
instruments or new data resources are released. In a relational database management
system, capturing these new data types often means re-design of a database schema,
which is generally a complex and costly process. However, in a research setting this in-
formation is often of great importance and can impact on our understanding of the
roles of genes and pathways in disease networks. A framework that facilitates the rapid
and seamless inclusion of new data types would therefore be particularly well-suited to
support the dynamic and ever-changing requirements of biomedical research commu-
nity. Graph databases are a natural way to represent highly connected, non-uniformly
distributed, semi-structured and unpredictable data as found in many biological sys-
tems studies [3, 4]. They also offer agile and flexible solutions and easily allow the in-
clusion of new data types.
Recently, there has been much interest in network representations of biological sys-
tems, particularly for network visualisation and network analytics. Several successful
frameworks have been established and used to support bioinformatics analysis includ-
ing, but not limited to, Cytoscape [5], Gephi [6] and NetworkX [7]. However, the tools
currently available are primarily for visualisation and analysis of network properties and
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ively work with datasets that are too large to visualise. Graph databases can naturally
complement such tools and methods, by offering this much-needed extra functionality.
Several graph-based approaches have been developed for biological data integration
such as Biozon [8], BN++ [9], Ondex [10, 11], and BioMine [12]). Some approaches, al-
though providing network views, use an underlying relational database (e.g. BN++).
The Ondex platform is a data warehouse using a graph data model and has been ap-
plied to plant systems biology, a domain where the data is typically fragmented across a
large number of data sources and often poorly annotated. More recently, Bio4j [4] uses
a graph database (Neo4j) to integrate data from several major repositories such as
Uniprot KB [13], Gene Ontology (GO) [14], RefSeq [15], NCBI Taxonomy [16], and
Expasy Enzyme DB [17].
The need to move towards considering graphs as biological knowledge repositories is
particularly evident in the biomedical domain. Many important diseases have now been
extensively researched for decades and the amounts of knowledge accumulated are
both vast and heterogeneous. The large volume of interconnected data means that its
exploration using a network visualizer cannot be carried out easily and the heterogen-
eity of the data can make cost-effective management difficult in a relational database
system.
In this work, we have explored the potential of using a graph database to facilitate
data management and analysis in order to provide biological context to disease-related
genes and proteins. This application case used the well-established Neo4j graph data-
base for building and querying a prototype disease map for a complex disease, such as
asthma. Neo4j has a free community edition that can be run as a lightweight desktop
database as well as a database server, and an SQL-like versatile query language for
graphs called Cypher. The database comes with an immediately available easy-to-use
web interface that can display the results as both graphs and tables and also has inter-
faces to R, Python and Java - core languages of modern bioinformatics research.
We have integrated information from human protein-protein interactions, pathways,
sequence similarity, disease-gene, gene-tissue and protein-drug associations. The se-
lected examples are intended to illustrate how the Neo4j Cypher query language can be
used to perform complex queries on this integrated dataset. We also show how infor-
mation from gene expression studies can be easily added to the database and how the
database can provide biological context for these differentially expressed genes. The
main advantage of presented approach is in its ability to contextualise disease-
associated genes by facilitating the identification and visual exploration of their network
neighbourhood. In addition, as we have already explained, graph databases excel in
traversal-type queries, facilitating the exploration of chains of connected concepts. This
‘link discovery’ can lead to new hitherto unexpected relationships being identified.
Therefore, in our application case we have aimed to explore both of these data mining
strategies, namely discovering connections between different entities of biomedical
interest (queries in Listings 1, 2 and 5) and characterising the relevant context of dis-
eases and biomarkers (queries in Listings 3 and 4).
The knowledgebase we constructed is organised according to the following principles.
First, we integrated several typical multi-omics data (sequence similarity, transcripto-
mics metabolic pathways and protein-protein interactions), which provide a low-level
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Then we have added the more general information that relates these lower-level entities
to the higher-level processes – e.g. different diseases. The queries presented here are
intended to provide illustrative examples about how to leverage connections across
these two levels – for example, by discovering links in the multi-omics layer relevant to
understanding the differences between different related diseases or using that informa-
tion for suggesting drug targets.Methods
A graph database offers several options for representation of data. Connections be-
tween entities (i.e. nodes) can be encoded directly as edges linking them together (e.g.
protein A interacts with protein B, where the edge between the nodes represents the
‘interacts with’ relationship). Additionally, properties can be associated with nodes (e.g.
protein A has annotation X, where ‘has annotation X’ is a property of the node repre-
senting protein A), and nodes that share a given property could be understood to be
linked. And lastly, nodes can be linked via edges to an intermediate node indicating a
common property (e.g. membership in the same pathway, for example node i repre-
senting protein A is connected to node j, representing pathway P by an edge that de-
scribes the relationship ‘participates in’). For this application case, the choice was
guided primarily by the concerns of efficiency in capturing the structure of the data.
For example, a property is an appropriate choice when annotation is simple, like a cat-
egory label. An edge can have properties of its own, so can capture situations where
the relationship is qualified, like a protein-protein interaction with given methods (e.g.
2-hybrid, anti tag co-immunoprecipitation) and associated with a confidence score.Data sources imported
All data used in this application case were imported into the Neo4j v2.3.1 graph data-
base. The integration was done from a protein-centric perspective, where the nodes
corresponding to the individual entries in the human subset of UniProt/Swissprot
served as key anchoring points for all other types of annotation. As many of the data-
bases we used are continuously updated, the point of reference when all data were ac-
quired for this study is 27/03/2015. Sequence similarity was determined by running all
versus all Tera-BlastPTM for the UniProt Human reference proteome on the Timelogic
DeCypher system. The significance threshold was 1e − 05, with effective database size
adjusted to 16.9 bln bases. The results were further processed by retaining bi-
directional hits only and modelled in the graph database as sequence similarity edges.
The set of sequence similarity data was refined to exclude duplicates based on the
UniProt id pair: the similarity between protein1-protein2 and protein2-protein1 was
represented by a single, undirected edge. A score was assigned to each edge, calculated
as a negative log10 of the average of the two e-values; only hits for which the ratio be-
tween the alignment length and the shortest sequence was above 0.60 were included.
Protein-protein interaction data were imported from the EBI IntAct database [18]
(PSI-MI tab format). Each interaction edge was annotated with a list of experimental
methods supporting it, as well as a confidence score (as given by the IntAct database).
Data about human metabolic pathways were acquired from the Reactome database (see
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them to proteins to indicate pathway membership. Data about protein association with
particular diseases were modelled in a similar way. The diseases, as defined by the cu-
rated subset of DisGeNET [20] (2014 release), were likewise represented as nodes with
edges connecting them to corresponding proteins; (mapping gene names to UniProt
identifiers was done via the Restful web services API of the UniProt database). Data on
approved drug compounds were downloaded from DrugBank [21] on 27/03/2015 as
DrugBank csv files. Where such information was available, those compounds were
linked to proteins they target via UniProt identifier references. Data on gene
expression-tissue enhanced association have been downloaded from the Human Protein
Atlas (HPA), (version 13), [22], and integrated in the database. The tissue types were
represented by nodes in the graph database and the enhanced expression in particular
tissue types were modelled as edges, with RNA-TS-FPKM values as property. Informa-
tion on ENSEMBL ids, (used for gene identification within HPA), was mapped to Uni-
Prot ids using the ‘Retrieve/ID mapping’ tool from the UniProt database, and noted as
a property of the Protein node.
We have included a set of high-confidence manually curated genes believed to be im-
plicated in one of the respiratory diseases as identified by Kaneko et al. [23]. The review
categorized genes into four partially overlapping subsets of Bronchial Asthma (BA),
Chronic Obstructive Pulmonary Disease (COPD), Essential hypertension (E-HTN) and
Tuberculosis (TB). TB and E-HTN are included in the list as controls [23]. The gene
names given in the paper were manually resolved to the UniProt identifiers and
imported as a list attribute of corresponding annotations. This resulted in 219 genes
(104 BA, 58 COPD, 35 TB, 54 E-HTN); detailed information on these gene sets is given
in Additional file 1: Table S4. This type of information, gathered typically from domain
experts or from careful study of the literature, is important in disease network con-
struction as it serves as a starting point to explore pathways and processes that may be
associated with the disease phenotype.
New experimental data may have significant impact on hypothesis generation on dis-
ease mechanisms. High-throughput transcriptomic experiments are a common original
source of such new information, and are routinely used to identify lists of new potential
candidate genes of biomedical interest. To evaluate the suitability of graph databases
for management and integrative analysis of these data types we have included several
such studies from the GEO database. We have extracted gene expression data from
three asthma-related GEO studies, namely GSE27876, GSE43696 [24] and GSE63142
[25]. Specifically, the GSE27876 series includes 5 normal control (NC), 5 mild asthma
(MiA) and 5 severe asthma (SA) samples, the GSE43696 series: 20 NC, 50 mild-
moderate asthma (MMA) and 38 SA samples, and the GSE63142 series: 27 NC, 72
MMA and 56 SA samples. Gene expression data analysis was conducted on the
GPL6480 platform [Agilent-014850 Whole Human Genome Microarray 4x44K G4112F
(Probe Name version)], within all these series. The identification of the differentially
expressed genes (DEGs) between asthma subtype/control cohorts was carried out using
the limma Bioconductor package [26]. The gene name (given by ENSEMBL identifier)
was mapped to the UniProt identifier, (again, via the ‘Retrieve/ID mapping’ tool from
the UniProt database), with the UniProt identifier represented as a node in the graph
database and the related ENSEMBL information as node property. Figure 1 illustrates
Fig. 1 The data model for inclusion of results from gene expression studies. The Protein nodes, (blue), are
associated to the GEO Comparison nodes (grey) by the DEG RELATED TO edges, (red); relationships between
GEO Comparison and GEO Study nodes (green) are represented by the PART OF edges, (green). The key for
i) the Protein node is given by the UniProt identifier, ii) the GEO Study node by its name and iii) the GEO
Comparison node by the GSM samples that are compared. Information on adjusted p-values of the differentially
expressed genes is stored as a property for the DEG RELATED TO edges. This simplified illustration includes only
10 differentially expressed proteins for the GSE43696 study [24], with similar representation for other studies.
NC: normal control; MMA: mild-moderate asthma; SA: severe asthma
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parisons that are ‘part of ’ the study. A ‘GEO Comparison’ node is related to the GSM
samples (from the GSE series) and describes which sample groups are compared
(e.g. normal control and mild-moderate asthma, NC - MMA). The Protein node is
linked to the GEO Comparison node by the ‘DEG RELATED TO’ edge, (with the
adjusted p-value of the DEG analysis). In this paper, the UniProt identifier gives
the label of the Protein node, but other information (e.g. gene name) can be
chosen from the Neo4j interface to be displayed as the label as well. Information
on the ENTREZ gene name and the protein name, specific to the Protein nodes
shown in Fig. 1, is given in Additional file 2: Table S5a.
Figure 2 illustrates the structure of the graph database and Table 1 gives details of
the data imported into the database in terms of nodes and edge types. Information to
add was checked with already stored data before each adding step in order to avoid du-
plicates. Thus, the UniProt identifier, (i.e. the key of the Protein node), can be uniquely
retrieved in the graph database. Similarly, names of diseases, pathways, tissues, GEO
studies, (i.e. the keys for the Disease, Pathway, Tissue, GEO Study nodes, respectively),
were checked for duplicates. The microarray data in the figure is also resolved to
Fig. 2 The Data Model: Schematic representation of biological information on proteins, pathways, tissues,
disease and drugs, and the names of the GEO data sources, (GEO Study id, GSM sample type comparison),
represented by nodes in the graph database. Relationships between these entities are shown by edges and
refer to associations between: a) protein-tissue, (TISSUEENHANCED); b) protein-pathway (IN PATHWAY);
c) protein-disease (BIOMARKER, GENETIC VARIATION, THERAPEUTIC, KANEKO ASSOCIATION); d) protein-drug
(DRUG TARGET, DRUG ENZYME, DRUG CARRIER, DRUG TRANSPORTER), e) protein-protein (PPI ASSOCIATION,
PPI COLOCALIZATION, PPI GENETIC INTERACTION, SEQ SIM); f) protein-GEO Comparison (DEG RELATED TO)
and g) GEO Comparison-GEO Study (PART OF)
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profile alternative splice variants and will therefore map to different protein ids. Rela-
tionships between entities, (i.e. edges), were also checked for duplicates based on keys
given by pairs of the involved entities; for example, the key of the Biomarker relation-
ship between the Protein and Disease nodes is given by the pair composed from the
UniProt identifier and disease name. Only when modelling associations between DEG
and GEO comparison/study, the key was taken as a triplet composed from the UniProt
identifier, the GEO Comparison name and the GEO Study identifier, given that the
GEO comparison names are not unique among all GEO studies integrated in this data-
base. Detailed information on node and edge occurrences is given in Table 1.Data modelling strategy
Unlike the relational database, where tables and relationships are heavily influenced by
technical constraints formalized as “normalization rules”, graph databases offer much
more flexibility and are more closely guided by the needs of the intended application.
For this application case we have chosen the entities that correspond to either logical
or real entities of biomedical interest. From the multi-omics perspective, the two phys-
ical entities central to our application case are proteins and drugs. These can be mem-
bers of multiple thematic sets – e.g. the proteins can be grouped by disease
involvement, tissue and metabolic pathway and drugs can be linked to particular dis-
eases. To allow us to explore the potentially complex inter-relationships between these
sets, they are also represented as nodes and therefore can be referenced directly as part
of the query pattern. The edges are used to indicate both i) the membership of an
Table 1 Overall occurrences and types of nodes and relationships included in the graph database









(b) Types and occurrences of relationships
Node type Edge type Node type Occurrences
Protein BIOMARKER Disease 17216
Protein THERAPEUTIC Disease 1209
Protein GENETIC_VARIATION Disease 2612
Protein KANEKO_ASSOCIATED Disease 251
Protein IN_PATHWAY Pathway 26085
Protein PPI_ASSOCIATION Protein 66678
Protein PPI_COLOCALIZATION Protein 1162
Protein PPI_GENETIC_INTERACTION Protein 43
Protein SEQ_SIM Protein 92089
Protein TISSUE_ENHANCED Tissue 4434
Protein DRUG_TARGET Drug 6429
Protein DRUG_ENZYME Drug 3204
Protein DRUG_TRANSPORTER Drug 1529
Protein DRUG_CARRIER Drug 222
GEO Comparison_test PART_OF GEO Study 9
Protein DEG_RELATED_TO GEO Comparison_test 87849
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of relationships between individual entities (e.g. protein interacts with other
protein).
The level of the detail was chosen in accordance with the need of our intended
application case. For example, in theory it may be valid to model an interaction
as a concept rather than an edge and then link it to specific tissues to indicate
whether it can occur there. However, by doing so an extra node and two edges
will be introduced into the graph, which will increase the computational com-
plexity of querying the database and make query construction more challenging
for the user. In this case, due to the applied nature of the work presented here,
it was therefore more appropriate to opt for a more generalized representation.
However, we recognize that often it may be necessary to develop detailed repre-
sentations in order to capture provenance and in the case of broad-content ra-
ther than thematically focused resources. To demonstrate how such a scenario
can be accommodated in Neo4j, we have modelled transcriptomics component of
our dataset in a way that captures all information about its provenance
Lysenko et al. BioData Mining  (2016) 9:23 Page 9 of 19(GEOStudy node), experimental design (GEOStudy to GEOComparison relation-
ship) and the analysis used (GEOComparison node) to process the data.Results
Here we illustrate the use of a graph database for facilitating hypothesis gener-
ation on disease mechanisms. We describe four queries related to asthma, a com-
plex respiratory disease whose symptoms include airway inflammation and
remodelling. Asthma is associated with multiple phenotypes and co-morbidities
and has similarities to other respiratory diseases such as COPD. A significant
number of asthma patients do not respond to conventional corticosteroid therapy,
suggesting a complex underlying aetiology of this disease at both physiological
and molecular levels.Identification of common proteins between Asthma and COPD, TB and E-HTN
We first show a simple query that returns proteins, (given by UniProt identifiers),
which are common to asthma and other respiratory diseases, (COPD, Tubercu-
losis (TB), and essential hypertension (E-HTN) respectively) using information
from two sources, a review by Kaneko et al. (2013) [23] and, separately the
DisGeNET database [20]. The Cypher queries are shown in Listings 1 and
Listings 2, the visual schematic of the query pattern is shown on Fig. 3 and the
results are shown in alphabetic order based on the second disease name in
Table 2. Some details of the Cypher query are briefly explained in Additional file
3. We see more genes in common for asthma and COPD than for asthma and
the other two respiratory diseases as expected, although differences are dependent
on the data source used for comparison. While there is a degree of commonality
among results from these resources, inclusion of multiple data sources can
provide complementary information. Information on genes related to a simple
disease only, as reported in [23], is provided in Additional file 4.Fig. 3 A visual schematic representation of graph patterns matched by queries in listing 1 (a panel) and
2 (b panel)
Table 2 Common protein set between Asthma and COPD, TB and EHTN, respectively, based on
data from Kaneko et al. 2013 review [23] and the DisGeNET database [20]
Alter disease Uniprot id set (Kaneko) Uniprot id set (Disgenet)
Hypertension, Essential [P29474, P04040, P12821, P07550, P30711] [P35228]
Pulmonary Dis- Ease, Chronic Obstructive [P01375, O00206, P01137, P35225, P01584,
P29474, Q9BZ11, P07550, P12821, P09211,
Q96QV1, P09488, P16410, P05305]
[P35228, P09601, P01137,
P14780, P01375]
Tuberculosis, Pulmonary [P01579, P01920, P01911, P01584, P22301,
P29460, P05112, P13501, P11473, P01375,
O60603, Q9NR96]
[P13500]
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diseases using Kaneko et al. (2013) data [23]Listing 2: Cypher query to identify proteins common to asthma and other respiratory
diseases using DisGeNET data only [18]Providing biological context: comparison of the network neighbourhoods of differentially
expressed genes from two asthma studies
Queries can easily be performed to select differentially expressed genes and relate them
to the rest of the network. This example compares the network neighbourhoods of two
sets of differentially expressed genes (DEGs) between Normal Control (NC) and Severe
Asthma (SA) from two studies, GSE43696 [24] and GSE63142 [25]. In this example we
have restricted the network neighbourhood to include only links from the DEGs com-
mon to these two studies, to Reactome signalling pathways [19] and to respiratory dis-
eases. The Cypher query is shown in Listing 3, the corresponding pattern – in Fig. 4
and part of the resulting network is shown in Fig. 5. Similarly to Fig. 1, details on the
ENTREZ gene name and the protein name of the Protein nodes (Fig. 5) are included in
Additional file 2: Table S5b.
Listing 3: Cypher query to identify DEGs that map to asthma and other respiratory
diseases as well as to signalling pathways.
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proteins
We have queried for a set of drugs from DrugBank DB that target proteins of similar
sequence to known asthma biomarkers (associated to asthma disease through the Bio-
marker relationship in DisGeNET). The query, pattern and part of the relevant network
are shown in Listing 4, Figs. 6 and 7, respectively. The query can be easily extended to
include other disease-protein relationship types, (e.g. Therapeutic), other disease types,
(e.g. COPD), and filters for output, (e.g. for sequence similarity better than a threshold
value).
Listing 4: Cypher query to identify drugs associated with proteins that have sequence
similarity with asthma biomarkers.
Results obtained can be used to infer new associations between drugs and asthma
biomarkers. For example, although no direct association has been reported for the
P08727 protein (asthma biomarker) and Tenecteplase (drug), an indirect relationship
can be identified between these two entities given that the P05787 protein (KRT8 gene)
has sequence similarity with the P08727 protein, which was reported as a target for
Tenecteplase, (Fig. 7). Exploring such indirect relationships can be of interest in drug
development research. The ENTREZ gene name and the protein name for Fig. 7 are
provided in Additional file 2: Table S5c.Fig. 4 A visual schematic representation of graph pattern matched by query in listing 3
Fig. 5 Disease – Protein-Signalling pathways associations: Common set of normal control - severe asthma
DEGs for GSE43696 [24] and GSE63142 [25] series and their associations with respiratory diseases and signalling
pathways. Node colour: protein, blue; GEO Comparison, grey; pathway, violet; disease, yellow. Edges:
GEO comparison - GEO study relationship, grey; protein-pathway association, violet; DEG association,
red; biomarker, green
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Studies suggest that asthma patients may experience exacerbations early in the morning
(see for example [27]). Independently, considerable research efforts have been directed to-
wards identification of genes involved in mediating circadian rhythms (’clock’ genes). Explor-
ation of the relationships between circadian system disruption and lung disease
development, (including asthma), may identify new potential targets (e.g. proteins, path-
ways) for disease treatment and may give better insights in drug administration [27, 28].
The following example identifies all shortest paths in the graph between asthma disease and
a subset of core clock components (protein-coding genes that generate and regulate circa-
dian rhythms), where the corresponding UniProt identifiers were resolved using the “Re-
trieve/ID mapping” UniProt tool (Table 3). Results are shown in Fig. 8, based on the Cypher
query in Listings 5, with the ENTREZ gene names and the protein names given in Add-
itional file 2: Table S5d. This example illustrates how simple graph traversal queries have
the potential to assist in hypothesis generation by exploring relationships between concepts.
Listing 5: Cypher query to explore shortest paths (in terms of graph representation)
between core clock genes and asthma.
Shortest pathways (Fig. 8) between the Asthma node and the core clock genes
(Table 3) node include: a) Asthma – Q9UIL8 – P67870 – Q99743; b) Asthma –
Fig. 6 A visual schematic representation of graph pattern matched by query in listing 4
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[P09211, P01375, P13569] – [Q12933, P28799] – Q16526. The O15516 protein
(encoded by the CLOCK gene) is linked through Sequence Similarity and PPI relation-
ships by Q99743 (NPAS2) and O00327 (ARNTL/BMAL1), respectively, and the protein
Q49AN0 (CRY2) has sequence similarity with Q16526 (CRY1). Interestingly, the
O15534 protein, encoded by PER1, also a core clock gene, (Table 3), does not lie within
3 steps of Asthma and is not an immediate neighbour of any of the other core clock
components in Table 3, that are within 3 steps of Asthma, (Fig. 8). We further queried
for the shortest paths between O15534 (PER1) and the rest of the core clock gene sub-
set (Table 3), using only association types related to protein-protein relationships, such
as sequence similarity and PPI; the Cypher query is given in Listings 6a, in Additional
file 5. The resultant network indicates that, in terms of topological distance, PER1 is
closer to PER2, CRY1 and CRY2 than to CLOCK, ARNTL/BMAL1 and NPAS2 (refer to
Fig. 9a).
Durrington et al. [27] suggest the possibility of the disruption of clock genes affecting
airway inflammation through a possible link of clock proteins to the immune response
involving REV-ErbA-alpha. The graph network can be queried for P20393 (REV-ErbA-
alpha) which does not appear on the shortest paths network in Fig. 8, but lies 3 stepsFig. 7 Drugs that target proteins, which have sequence similarity to asthma biomarkers. No information on
direct target interaction between these drugs and biomarkers is given in the database a priori. Nodes
colours: protein, blue; disease, yellow; drug, red. Edges: drug-target associations, red; sequence similarity
relationships, grey; biomarker, green
Table 3 Gene symbols and corresponding UniProt identifiers, (resolved via the “Retrieve/ID
mapping” tool), for the core circadian components








Lysenko et al. BioData Mining  (2016) 9:23 Page 14 of 19from O00327(ARNTL/BMAL1) and Q99743(NPAS2), (Cypher query given in Listings
6b, in Additional file 5 and output results in Fig. 9b).
Discussion and conclusions
High volume datasets are being routinely generated in systems biomedicine. An on-
going concern for the interpretation of these data is that biological information has a
challenging mix of complexity and rich semantics. Modelling of data in graph database
ideally are guided by the same principles as those used for ontology design. In a way,
the ontology may play the same role as a schema plays in a relational database by defin-
ing a valid set of relationships and/or properties that can exist for particular entities or
their combinations. However, for this application case we have elected not to explore
this topic in great detail in order to keep focus firmly on the applied aspects of man-
aging biomedical data using the Neo4j database and to present it at a level accessible to
a more general audience. For completeness, we would like to point out that from the
ontology-centric data modelling perspective a Neo4j graph can be thought of as aFig. 8 Shortest paths (of length < 4) between core clock components (red squares) and asthma-related proteins in
the network. Node colour: disease, yellow; protein, blue. Edges: KANEKO association, blue; PPI association,
red; sequence similarity relationship, grey
Fig. 9 Shortest path queries to explore relationships between a) the O15534 protein (PER1 gene) and b)
the P20393 protein (REV-ErbA-alpha gene) and the circadian core genes, (Table 3). a In terms of distance in
graph, the O15534 protein (PER1 gene) (red square), transcriptional repressor, is closer to O15055 (PER2),
Q16526 (CRY1) and Q49AN0 (CRY2), (transcriptional repressors), than to O15516 (CLOCK), O00327 (ARNTL/
BMAL1) and Q99743 (NPAS2), (transcriptional activators). The circadian core genes are shown by black
squares. b The P20393 protein (REV-ErbA-alpha gene) (red square), suggested to be involved in the
disruption of clock genes [27], can be seen 3 steps away from the O00327(ARNTL/BMAL1) and
Q99743(NPAS2) core clock genes (black squares). Node colour: protein, blue. Edges: PPI association,
red; sequence similarity relationship, grey
Lysenko et al. BioData Mining  (2016) 9:23 Page 15 of 19collection of instances of data, where node “Labels” are equivalent to classes, and types
of edges – to relationship types. Another important consideration in choosing how to
represent the data is the performance constraints. [Note: We would encourage devel-
opers to look at the Neo4j features relating to Cartesian product warning and to query
flow diagnosis, using the EXPLAIN and PROFILE features provided.] In this respect, as
we were specifically interested in exploring the applications of the link discovery type
of queries in a biomedical setting, it was necessary to ensure both the compactness of
paths and adequate annotation necessary to ensure that the traversal space can be com-
puted, e.g. it does not produce an all-versus-all set of entities as part of computing the
solution (a “Cartesian product”).
In traditional relational databases approaches, the technical structure often gets in
the way of exploratory data analysis either by visualisation or through data mining tech-
niques. Graph databases (explored here with Neo4j) offer a powerful but lightweight,
intuitive and flexible solution that is more readily compatible with a biological network
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biological data. This study shows how a combination of a powerful query language (to
narrow down the search space) with network visualisation can help data exploration
and hypothesis generation. The use of graph database approaches has some similarities
with previous systems for logic-based modelling of integrated datasets [29, 30].
As we have illustrated in this work, graph databases offer many features that make
them a particularly attractive option for a research-based setting, in particular in cases
where it might be necessary to dynamically develop and interactively mine heteroge-
neous and not uniformly inter-related data. However, we would like to stress that in
our opinion graph databases are best thought of as a complement to relational database
technologies. There will clearly be cases where a relational database solution will be
preferable, especially when data are dense and naturally fit the tabular representation
where relational databases would offer much better processing performance.
Another important consideration is the place of Neo4j in a wider family of NoSQL
and especially graph databases. The concept of graph databases is still relatively novel
and therefore currently there are multiple alternative systems under active develop-
ment. However, one standard – Resource Description Framework (RDF) and its enab-
ling technologies (triple stores and SPARQL query language) have gained particular
prominence due to their importance for Semantic Web and Internet-powered federated
data solutions. For this reason we would like to further elaborate on the differences be-
tween these two standards and specifically the roles they could potentially play in man-
agement of large biomedical datasets.
Neo4j database belongs to the family of “Property graph” databases, which in contrast
to RDF have conceptually distinct property elements that can be attached to both
nodes and edges. In some respects, this syntax may be more familiar to users of object-
oriented languages, as in contrast to RDF, there is neither a global uniqueness con-
straint nor specifically required format for node identifiers. In combination, these fea-
tures make graph query syntax more compact and easier to read. Given that the Neo4j
database is inherently a “closed world” solution, it is possible to collect the entirety of
meta-data about the types and number of different entities and relationships between
them, which can then inform further exploration. As SPARQL and RDF are primarily
designed to operate in an “open world” setting of the Semantic Web, creating such
summaries may not always be possible or can be very computationally intensive.
However, we would like to acknowledge that the RDF formalism does have its un-
disputed advantages in facilitating integration and exchange of distributed data and
issues like lack of properties on edges can be addressed by leveraging more advanced
features like reification or named graphs. In our view, the matter of preferences
between the properties databases like Neo4j or RDF triple stores comes down to
whether a particular application case can actually benefit from the extra features
available via Semantic Web technologies. As adopting such technologies will inevitably
come with considerable costs in terms of technical overhead and increased complexity,
property databases may be preferable when speedy and flexible development of a single
non-federated resource is the ultimate requirement.
The lack of schema in Neo4j may also be somewhat of a double-edge sword: although
it does offer much flexibility, it also removes the interoperability standard from the
data, which may make sharing and management of large distributed projects datasets
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ent semantics by binding critical attribute names and/or values of nodes and edges to a
consensus controlled vocabulary. In a biomedical domain, this controlled vocabulary
will likely come in the form of a suitable ontology. The ontologies could then provide a
de-facto data modelling standard and many key concepts in the biomedical domain
have already been modelled by projects like SNOMED [31], MeSH [32], GO [33] and
OBI [34], with several hundred of other more specialized ontologies available from the
OBO foundry [35] and NCBO Bioportal [36] repositories. Although at present the
availability of advanced ontology-based features, like reasoning and data validation, var-
ies in different graph databases, some notable solutions do offer examples of very close
integration - e.g. the already-mentioned graph databases based on the resource descrip-
tion framework (RDF) [37].
We have explored here the utility of a graph database in providing a powerful yet
flexible solution for disease network representations and for exploratory data mining
and analysis to support hypothesis generation on disease mechanisms. Our study sug-
gests that the Neo4j system offers a level of performance and an appropriate query and
visualisation interface to effectively mine and manipulate these data. In particular, we
have found the Cypher graph query language to be of great utility, because, as illus-
trated by our sample queries, it enabled us to generate a representative selection of
common biologically-motivated queries with minimal efforts. As systems medicine pro-
jects continue to generate large amounts of heterogeneous datasets, graph database ap-
proaches may offer useful solutions for their knowledge management.
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